Premarket Biotech Digest – $DCPH reports positive data, $LIVN inks new deal, $JNJ receives EC nod

By |November 21st, 2017|Digest|

Deciphera Pharmaceuticals Inc. ($DCPH) reported positive interim data from a Phase 1 clinical trial evaluating its lead candidate DCC-2618 in patients with malignant gliomas. Off four evaluable patients with glioblastoma multiforme (GBM), one experienced a partial response with 94% tumor reduction at week 84. [...]

Jazz Pharmaceuticals looks promising with Q3 results $JAZZ

By |November 17th, 2017|Monthly Investment Ideas|

Jazz Pharmaceuticals ($JAZZ) is a pharma company with a highly diversified product portfolio. It has drug candidates for a wide range of conditions. However, the company is grappling with a number of issues as well. On the positive side, the company recently announced receiving the FDA approval for its drug [...]

Premarket Biotech Digest – $TCON reports +ve data, $IONS starts new trial, $GSK received EC approval

By |November 14th, 2017|Digest|

Tracon Pharmaceuticals ($TCON) reported positive results from a  Phase 1 clinical trial assessing TRC102 (methoxyamine) and the chemo agent Fludara (fludarabine) in patients with advanced blood cancers. The program had enrolled 20 patients with a range of blood cancers. Each received one of five [...]

Bioverativ looks strong after reporting strong Q3 results $BIVV

By |November 10th, 2017|Monthly Investment Ideas|

Bioverativ Inc. ($BIVV) recently reported its third quarter financial results. The company reported 27.2 percent Year over Year increase in its quarterly revenue to $291.6 million. However, its GAAP net income dropped 15.7 percent and its GAAP EPS dipped 16 percent to $0.63.  Bioverativ showed increase in its Non-GAAP metrics [...]

Premarket Biotech Digest – $KERX gets FDA nod, $CBMG opens China facility, $MDT gets CE mark

By |November 7th, 2017|Digest|

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the FDA has approved its Auryxia for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. Auryxia is the only oral treatment option available in the market which is developed and approved [...]

AbbVie Reports Strong Quarterly Results, Fueling Stock Growth $ABBV

By |November 3rd, 2017|Monthly Investment Ideas|

AbbVie Inc. ($ABBV) recently reported its financial results for the third quarter. The company’s adjusted EPS for the quarter stood at $1.41 while its net revenue was reported at $6.995 billion. AbbVie also reported 15.8 percent increase in its Humira revenue. It reported solid growth for its Imbruvica product with [...]

Premarket Biotech Digest – $MRK withdraws marketing application, $DEPO settles dispute, $BHVN announces new collaboration

By |October 31st, 2017|Digest|

Kura Oncology Inc. ($KURA) announced encouraging preclinical data on leukemia candidate KO-539, a selective inhibitor of the menin-MLL protein-protein interaction. The drug candidate showed significant activity in new genetically defined subsets of acute myeloid leukemia, beyond the original target of MLL-rearranged leukemias. The company [...]

Amgen stock set to grow as the company reports strong Q3 results, revises guidance $AMGN

By |October 27th, 2017|Monthly Investment Ideas|

Amgen Inc. ($AMGN) reported upbeat third quarter financial results. The company announced 3 percent increase in its GAAP earnings per share to $2.76, while its non GAAP EPS increased 8 percent to $3.27 driven by higher operating margins. However, the decline in the company’s revenue continued as it reported 1 [...]

Premarket Biotech Digest – $VICL inks new deal, $VIVO receives FDA warning letter, $ALXN gets approval

By |October 24th, 2017|Digest|

Intercept Pharmaceuticals ($ICPT) stock shot up as the company announced positive results for its from a Phase 2 clinical trial, AESOP, evaluating obeticholic acid (OCA) for the treatment of primary sclerosing cholangitis. The company reported that patients receiving 5 mg OCA per day (with [...]

Alexion stock stands to benefit from upcoming Q3 results and restructuring efforts $ALXN

By |October 20th, 2017|Monthly Investment Ideas|

Alexion Pharmaceuticals Inc. ($ALXN) is scheduled to announce its third quarter results on October 26, 2017. The company is expected to report strong results, which may act as a positive catalyst for the stock. Alexion had announced positive results for the second quarter where its total revenue grew 21 percent [...]

Premarket Biotech Digest – $IMDZ to start new trial, $ANIK reports approval, $AMGN announces new collaboration

By |October 17th, 2017|Digest|

Aimmune Therapeutics ($AIMT) announced its new clinical trial collaboration with Regeneron Pharmaceuticals and Sanofi for testing AR101 with adjunctive DUPIXENT (dupilumab) in patients with peanut allergy. The planned Phase 2 study is expected to start next year. It will involve examining patients' desensitization to [...]

AbbVie stock to retain momentum on the back of drug approval and Humira case $ABBV

By |October 13th, 2017|Monthly Investment Ideas|

AbbVie Inc. ($ABBV) stock continues its positive run on the back of several positive events. The company is working towards making its portfolio more diverse and to reduce its reliance on its star performer Humira. It recently announced the FDA approval of its Mavyret for treating Hepatitis C virus genotype [...]

Premarket Biotech Digest – $KTOV buys stake, $JNJ reports positive results, $NVS receives CE mark

By |October 9th, 2017|Digest|

Kitov Pharmaceuticals ($KTOV) announced that it has acquired an additional 27% stake in privately held TyrNovo, a developer of small molecule oncology drugs. The company now controls nearly 92 percent stake in TyrNovo. In this latest transaction with a group of minority shareholders, Kitov [...]

Acadia Pharmaceuticals boosts position in Parkinson’s disease market ($ACAD)

By |October 6th, 2017|Monthly Investment Ideas|

Acadia Pharmaceuticals Inc. ($ACAD) is one of the most prominent players in Parkinson’s disease market. The company also has presence in other related markets including Alzheimer’s. Acadia’s recently reported strong financial numbers for its second quarter. The company’s net loss for the quarter stood at $0.55 per share, lower than [...]

Premarket Biotech Digest – $VICL stock shoots up, $MNK announces new deal, $AST announces positive results

By |October 3rd, 2017|Digest|

Vical Inc. ($VICL) announced that the FDA has advised the company that a single successful Phase 2 clinical trial may be sufficient to support approval of antifungal VL-2397 under Limited Use Indication (LUI) status. The company plans to start its mid-stage study this quarter [...]

Shire Plc stock looks attractive ahead of EU decision on eye drug $SHPG

By |September 29th, 2017|Monthly Investment Ideas|

Shire Plc ($SHPG) stock showed strong recovery after hitting its 52 weeks low. The stock’s strong movements indicate the reversal of downward trend and the stock looks attractive at current price point. The company is currently in the process of its corporate restructuring, which is expected to result in more [...]

Premarket Biotech Digest – $BTX reports positive data, $CPIX launches Totect, $JAGX inks new deal

By |September 26th, 2017|Digest|

ProQR Therapeutics ($PRQR) stock shot up as the company reported positive preliminary results from a Phase 1b clinical trial assessing QR-010 for the treatment of cystic fibrosis (CF) patients with the F508del mutation. QR-010 is an RNA-based oligonucleotide that targets the messenger RNA in [...]

Rigel Pharmaceuticals stock presents strong case ahead of FDA decision $RIGL

By |September 22nd, 2017|Monthly Investment Ideas|

Rigel Pharmaceuticals Inc. ($RIGL) recently reported receiving the FDA approval of its New Drug Application for Tavalisse in patients suffering from chronic or persistent immune thrombocytopenia. The company used its Phase 3 clinical program data for supporting the application. The data pertains to 163 patients suffering from the condition. The [...]

Premarket Biotech Digest – $FATE starts Phase 2, $OCX reports positive results, $PTIE receives new grant

By |September 19th, 2017|Digest|

Fate Therapeutics ($FATE) announced the start of Phase 2 segment of its Phase 1/2 clinical trial, PROTECT, assessing ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with blood cancers undergoing matched unrelated donor hematopoietic cell transplantation. The Phase 2 study will [...]

Ionis Pharmaceuticals makes strong move with new drug filing $IONS

By |September 15th, 2017|Monthly Investment Ideas|

Ionis Pharmaceuticals Inc. ($IONS) took an important step ahead with the recent filing of its New Drug Application (NDA) for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome. The company has already filed for the approval in the European Union as well. Ionis plans to launch the [...]

s2Member®